Description: Instem plc is a supplier of information technology (IT) applications to the early development healthcare market delivering solutions for data collection, management and analysis across the research and development continuum. The Company is engaged in Global Life Sciences operations. Its lead product suite, Provantis, is an application in the Early Development Safety Assessment (EDSA) market. The Provantis solution incorporates a suite of modules required for managing and recording EDSA studies, from receipt of the compound through to the automated assembly of statistical analyses and final reports. Its software allows scientific staff to collect, analyze and share data across the organization and externally. It also offers ALPHADAS, an early phase clinical software solution. The Company offers Centrus suite, which provides pre-built applications, as well as the ability to utilize a range of business intelligence and analysis tools.
Home Page: www.instem.com
INS Technical Analysis
Diamond Way
Stone,
ST15 0SD
United Kingdom
Phone:
44 17 8582 5600
Officers
Name | Title |
---|---|
Mr. Phil J. Reason | CEO & Exec. Director |
Mr. Nigel John Goldsmith | CFO, Sec. & Exec. Director |
Ms. Marybeth Thompson | Chief Operating Officer |
Dr. Gordon Smith Baxter | Chief Scientific Officer |
Mr. Vince D'Angelo | VP of Governance, Risk Management & Compliance |
Mr. Gary Mitchell | VP of Global Marketing |
Mr. Adrian Gare | VP of Corp. Devel. |
Ms. Eve Leconte | Head of People Services |
Mr. Mike Harwood | Exec. VP of Regulatory eStudy Solutions |
Mr. Gregor Grant | Exec. VP of Preclinical Solutions |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Technology |
GIC Sub-Industry: | Health Care Technology |
Forward PE: | 19.6078 |
---|---|
Trailing PE: | 85.1875 |
Price-to-Book MRQ: | 3.1421 |
Price-to-Sales TTM: | 3.0395 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 485 |